| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T22 |
0-170 |
Sentence |
denotes |
Here, we provide an industry regulatory perspective on durable learnings and innovation that may emerge from the COVID‐19 experience; they fall into two major categories. |
| T23 |
171-361 |
Sentence |
denotes |
First would be innovation in clinical trials and regulatory frameworks, enabled by digital technologies that may increase the efficiency and acceptability to both patients and investigators. |
| T24 |
362-621 |
Sentence |
denotes |
Second is the application of the same level of regulatory urgency, responsiveness, and flexibility in requirements seen with COVID‐19 solutions to other serious life‐threatening and/or debilitating diseases that remain major causes of mortality and suffering. |
| T25 |
622-663 |
Sentence |
denotes |
These are described in more detail below. |
